| 产品描述: | Tolebrutinib (SAR442168) 是一种有效的,选择性,具有口服活性和可透过血脑屏障的布鲁顿氏酪氨酸激酶 (BTK) 抑制剂,在 Ramos B 细胞和 HMC 小胶质细胞中的 IC50 值分别为 0.4 和 0.7 nM。Tolebrutinib 对中枢神经系统免疫具有功效。Tolebrutinib 可用于多发性硬化症 (MS) 的研究。 |
| 靶点: |
IC50: 0.7 nM (BTK; in HMC microglia cells);BTK |
| 体外研究: |
PRN2246 blocks the BCR-mediated activation (IC50=10 nM) and Fc receptor activation (IC50=166 and 9.6 nM for FcεR and FcγR, repectively) of immune cells. PRN2246 inhibits microglial FcγR activation through durable occupancy of BTK, with an IC50 of 157 nM. |
| 体内研究: |
PRN2246 (1-5 mg/kg; p.o. q.d. for 28 d) produces dose-dependent protection from in myelin oligodendrocyte glycoprotein (MOG)-induced experimental autoimmune encephalomyelitis (EAE) model. |
| 参考文献: |
1.. Dahl K, et, al. Radiosynthesis of a Bruton's tyrosine kinase inhibitor, [ 11 C]Tolebrutinib, via palladium-NiXantphos-mediated carbonylation. J Labelled Comp Radiopharm. 2020 Sep;63(11):482-487.
2. Francesco MR, et, al. PRN2246, a potent and selective blood brain barrier penetrating BTK inhibitor, exhibits efficacy in central nervous system immunity. Multiple Sclerosis Journal. 2017;Poster Session 2:P989. |
| 保存条件: |
-80℃(运输条件:冰袋低温运输) |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
2.195 ml |
10.977 ml |
21.953 ml |
| 5 mM |
0.439 ml |
2.195 ml |
4.391 ml |
| 10 mM |
0.22 ml |
1.098 ml |
2.195 ml |
| 50 mM |
0.044 ml |
0.22 ml |
0.439 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |